Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2’Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model. This evidence concerns the gene CD8A and melanoma.